

Date and Time: 25th March 2014

Minutes: Final

Guideline Development Group Meeting 6: Gallstone Disease

Place: Mercure, Portland Street, Manchester

Present: Gary McVeigh (Chair) (GM)
Elaine Dobson Evans (EDE)
Simon Dwerryhouse (SD)
Rafik Filobbos (RF)
Giles Toogood (GT)
Gerri Mortimore (GMortimore)
Kofi Oppong (KO)
Richard Sturgess (RS)
Luke Williams (LW)
Imran Jawaid (IJ)

In attendance:

<p>NICE Staff:</p> <p>Stephanie Mills (SM) James Hall (JH) Sarah Palombella (SP) Gabriel Rogers (GR) Ben Doak (BD)</p> <p>Apologies: Michael Heath (MH)</p>	<p>Steven Ward (Sward) Sheryl Warttig (SW) Sue Ellerby (SE) Hugh McGuire (HM)</p>	
---	---	--

Observers:

N/A		
-----	--	--

Notes

1. Introductions & guideline development group (GDG) working

GM welcomed the group and asked NICE staff members, HM and SP, to introduce themselves. The GDG were directed towards the minutes of the last meeting. These were accepted as an accurate record. GM asked all GDG members to give any declarations over and above the last

Notes

meeting. Nothing new was declared

GM then took the GDG through the agenda for the meeting and explained that the group would be hearing the results of the health economic modelling and finalising the recommendations, ready for draft guideline stakeholder consultation.

2. Health economics (Item 2)

SWard gave a recap on the structure of the health economic model, the inputs and parameters of the model, its strengths and limitations, and gave the final results and also the results of sensitivity analysis.

The GDG discussed the main results and felt that these would support the recommendations which had been made.

3. Recommendations revisit

Following the health economics, SW gave a presentation and took the GDG through the final recommendations and the limited additional evidence from the re-run searches which were conducted. The presentation also touched on feedback from the GDG on the draft guideline.

The GDG considered how the recommendations may need to be tweaked in light of the health economic evidence and also highlighted which recommendations would be key priorities for implementation of the guideline.

4. Research recommendations

SW led a discussion with the GDG on clinical areas where there was little or very low quality evidence to address some of the questions looked at within the guideline.

5. Implementation tools: costing presentation

PP presented to the group on the role of the costing analyst and how the tools that are produced alongside the guideline will support implementation and uptake of the guidance within the NHS.

6. Final review of recommendations

The recommendations were tweaked over lunch, following the GDG discussions in the morning. The GDG were asked to look at each of the recommendation to ensure they captured the spirit of what was intended.

7. AOB and next steps

SM explained the steps following the GDG meeting and advised the committee of when they needed to be available before the guideline is submitted to the NICE commissioning team for quality assurance, prior to stakeholder consultation. SM encouraged the group to remain engaged in the guideline development process and also reminded the GDG that they would not be eligible to comment on behalf of their respective organisations during the guideline consultation. SM confirmed that the GDG meeting post-guideline consultation would be on 25th July 2014. SM and GM thanked everyone for their hard work and commitment to the guideline.

Date of next meeting: Fri 25th July 2014